Appendix Table 1. Clinical parameters by site of first relapse

|  | Entire cohort  (n=98) | | Remission  (n=6) | ILR  (n=29) | DM  (n=58) | No imaging  (n=4) |
| --- | --- | --- | --- | --- | --- | --- |
| Demographics | | | | | | |
| Age, median [years] | 68 (34-80) | | 65 (57-75) | 68 (51-78) | 68 (34-79) | 74 (68-80) |
| Sex, male | 50 (51.0%) | | 2 (33.3%) | 14 (48.3%) | 33 (59.0%) | 0 (0%) |
| Preoperative Risk Factors | | | | | | |
| CTCs≥1 | 7 (7.1%) | | none | none | 7 (12.5%) | none |
| CA19-9 ≥ 200kU/l | 31/74 (41.9%) *24 missing* | | 2/4 (50%) *2 missing* | 10/25 (40%) *2 missing* | 18/42 (42.9%) *14 missing* | 1/2 (50%) *2 missing* |
| Tumour size on imaging> 25mm | 39/97 (40.2%) *1 missing* | | 2 ( 33.3%) | 15 (51.7%) | 21/57 (36.8%) *1 missing* | 1 (25%) |
| Bilirubin > 50µmol/L | 75/94 (79.8%) *4 missing* | | 5 (83.3%) | 20/27 (74.1%) *2 missing* | 47/56 (82.4%) *1 missing* | 2 (50%) |
| Treatment | | | | | | |
| Neoadj. CTX: GEMZ  FOLFIRINOX | | 3 (3.0%) 1 (1.0%) | none none | 2 (6.9%) none | 1 (1.7%) 1 (1.7%) | none none |
| Operation: PPPD  PD  tot. Pancreatect. | | 77 (78.6%) 13 (13.2%) 8 (8.2%) | 5 (83.3%) 1 (16.7%) none | 23 (79.3%) 4 (13.8%) 2 (6.9%) | 46 (79.3%) 7 (12.1%) 5 (8.6%) | 2 (50%) 1 (25%) 1 (25%) |
| Venous resection | | 36 (36.7%) | 3 (50%) | 16 (55.2%) | 15 (25.9%) | 1 (25%) |
| Adjuvant CTX FLV:  GEMZ:   FLOX  none: | | 53 (54.1%) 6 (6.1%) 3 (3.1%) 36 (36.7%) | 5 (83.3%) none none 1 (16.7%) | 14 (48.3%) 3 (10.3%) 1 (3.4%) 11 (37.9%) | 31 (53.4%) 3 (5.2%) 1 (1.7%) 22 (37.9%) | 2 (50%) none none 2 (50%) |
| Histopathologic results | | | | | | |
| Pancreatobiliary type Intestinal type | 97 (99%) 1 (1%) | | 6 (100%) | 28 (96.6%) 1 (3.4%) | 58 (100%) | 4 (100%) |
| UICC-stage (V7): Ib  IIa  IIb | 2 (2.0%) 23 (23.5%) 73 (74.5%) | | none 4 (66.7%) 2 (33.3%) | none 9 (31.0%) 20 (69.0%) | 1 (1.7%) 8 (13.8%) 49 (84.5%) | 0 (0%) 2 (50%) 2 (50%) |
| pN1-status | 73 (74,5%) | | 2 (33.3%) | 20 (69.0%) | 49 (84.5%) | 2 (50%) |
| R1-status | 61 (62.2%) | | 3 (50%) | 20 (69.0%) | 35 (60.3%) | 3 (75%) |
| Vascular infiltration | 64 (65.3%) | | 2 (33.3%) | 17 (55.1%) | 42 (72.4%) | 3 (75%) |
| Perineural infiltration | 91 (92.9%) | | 4 (66.7%) | 28 (96.6%) | 54 (93.1%) | 4 (100%) |
| Comparison of patient, tumour, and treatment characteristics between different subgroups and the entire cohort. One single patient with death unrelated to cancer omitted from the subgroup presentation ILR: isolated locoregional recurrence, DM: distant metastasis, CTC: circulating tumour cell, GEMZ, FLV, FLOX, FOLFIRINOX: chemotherapy regimens; PD: pancreato-duodenectomy, PPPD: pylorus preserving PD | | | | | | |